Exciting Collaboration Unveiled: Renhaim Inc. Partners with Geninus for Pancreatic Cancer Vaccine Development
We are thrilled to announce a groundbreaking partnership between Renhaim Inc. and Geninus, marked by the signing of a Memorandum of Understanding (MOU) on March 24, 2022. This strategic collaboration aims to spearhead the development of a mRNA-based pancreatic cancer vaccine, leveraging the cutting-edge Neoantigen Screening technology of Geninus.
Under the terms of the MOU, Renhaim Inc. will harness the unique bioinformatics capabilities of Geninus to identify antigen candidates for the mRNA pancreatic cancer vaccine.
The collaboration stems from ongoing discussions initiated in early 2022, where Renhaim and Geninus explored the potential of developing diverse cancer vaccines. Pancreatic cancer emerged as a focal point due to its marketability and perceived likelihood of success. Recognizing the substantial potential of the technology of Geninus, both companies have embarked on a joint development journey. In August 2022, following the MOU signing, we solidified our commitment by entering into an additional joint research and development agreement, marking the commencement of a comprehensive cancer vaccine development program.
Pancreatic cancer ranked fifth in global mortality rates according to OECD standards and lacks commercially available effective treatments. Renhaim is dedicated to addressing this critical gap through the development of an mRNA-based cancer vaccine that can be seamlessly integrated into combination therapy. Our mission is to contribute significantly to the advancement of pancreatic cancer treatment and bring hope to those with this formidable challenge.
We are committed to the rigorous research and development required for this ambitious endeavor, and we look forward to making a positive impact on the lives of many individuals affected by pancreatic cancer.
For more details, please refer to the link below.
Prev
Next
